Skip to main content
[Preprint]. 2022 Apr 12:2022.04.06.22272763. [Version 1] doi: 10.1101/2022.04.06.22272763

Figure 5. Vaccine efficacy (solid lines) in baseline SARS-CoV-2 seronegative per-protocol vaccine recipients by A) D29 ID50 titer in ENSEMBLE by geographic region (US, United States; Lat Am, Latin America; S Afr, South Africa); B), D57 ID50 titer in COVE, D29 ID50 titer in ENSEMBLE (US), D56 ID50 titer in COV002, all estimated using the Cox proportional hazards implementation of Gilbert et al.39.

Figure 5.

The dashed lines indicate bootstrap point-wise 95% CIs. The follow-up periods for the VE assessment were: A) ENSEMBLE-US, 1 to 53 days post D29; ENSEMBLE-Lat Am, 1 to 48 days post D29; ENSEMBLE-S Afr, 1 to 40 days post D29; B) COVE (doses D1, D29), 7 to 100 days post D57; ENSEMBLE-US, 1 to 53 days post D29; COV002 (doses D0, D28; VE defined as 1-relative risk of whether or not an event occurred = 28 days post-D28 till the end of the study period). The green histograms are an estimate of the density of D29 ID50 titer in ENSEMBLE (including by geographic region in A). The blue histograms are an estimate of the density of ID50 titer in baseline SARS-CoV-2 negative per-protocol vaccine recipients in COVE. Curves are plotted over the range from 10 IU50/ml to 97.5th percentile of marker for COVE and from 2.5th percentile to 97.5th percentile for ENSEMBLE. Baseline covariates adjusted for were: ENSEMBLE, baseline risk score and geographic region; COVE: baseline risk score, comorbidity status, and Community of color status; COV002: baseline risk score.